Grant: CIHR Fellowship
University of Calgary
$135,000.00
A systematic approach to understand the mechanism of immune cell infiltration and to enhance efficacy of immunotherapy in solid tumors
EF 2020-21
Résumé
Immunotherapy, such as immune checkpoint therapy (ICT), has given hope to millions of patients with advanced tumors that tumor is no longer an incurable disease, which is unimaginable with traditional therapies such as radiotherapy and chemotherapy. Immunotherapy has been the most promising option that could finally help us defeat cancers. The most famous story is from the former US president, Jimmy Carter, who received pembrolizumab (an anti-PD1 antibody) treatment and was totally recovered. ICT such as anti-PD1 treatment with pembrolizumab has a response rate of 100% in relapsed/refractory classical Hodgkin lymphoma. Unfortunately, though effective for blood cancers, there is only a 10-30% response rate in solid tumors, which accounts for more than 80% of all cancer cases. New immune checkpoint inhibitors are developed each year, but the improvement is not impressive due to one common reason: the therapy requires tumor infiltrated lymphocytes (TILs) (especially T cells) to be present in the tumors. The fact is 60-70% cancer patients bear "cold" tumors, which means there is no or few T cells within their tumor microenvironment. Increasing TILs in tumors has been a bottleneck for efficacy of immunotherapy. In some clinical studies, increased immune cell infiltration could enhance the response rate of anti-PD1 treatment by 2-4 folds. We have developed a method to classify tumors into "cold" and "hot" tumors, and systematic analyses on "hot" and "cold" tumors as well as single cancer cell sequencing datasets have successfully identified a set of cancer intrinsic factors that could affect the homing and retainment of TILs. We are validating these targets in mouse models and seeking to collaborate with medical sectors to bring our druggable targets to clinic which will hopefully increase efficacy of anti-PD1 treatment greatly.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
440663
Name
Li Lin
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
A systematic approach to understand the mechanism of immune cell infiltration and to enhance efficacy of immunotherapy in solid tumors
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Anti-Pd1 Therapy; Bioinformatics; Crispr; Hot And Cold Tumor; Immune Cell Infiltration; Immunotherapy; Single Cell Sequencing; Syngeneic Mouse Model
Abstract
Immunotherapy, such as immune checkpoint therapy (ICT), has given hope to millions of patients with advanced tumors that tumor is no longer an incurable disease, which is unimaginable with traditional therapies such as radiotherapy and chemotherapy. Immunotherapy has been the most promising option that could finally help us defeat cancers. The most famous story is from the former US president, Jimmy Carter, who received pembrolizumab (an anti-PD1 antibody) treatment and was totally recovered. ICT such as anti-PD1 treatment with pembrolizumab has a response rate of 100% in relapsed/refractory classical Hodgkin lymphoma. Unfortunately, though effective for blood cancers, there is only a 10-30% response rate in solid tumors, which accounts for more than 80% of all cancer cases. New immune checkpoint inhibitors are developed each year, but the improvement is not impressive due to one common reason: the therapy requires tumor infiltrated lymphocytes (TILs) (especially T cells) to be present in the tumors. The fact is 60-70% cancer patients bear "cold" tumors, which means there is no or few T cells within their tumor microenvironment. Increasing TILs in tumors has been a bottleneck for efficacy of immunotherapy. In some clinical studies, increased immune cell infiltration could enhance the response rate of anti-PD1 treatment by 2-4 folds. We have developed a method to classify tumors into "cold" and "hot" tumors, and systematic analyses on "hot" and "cold" tumors as well as single cancer cell sequencing datasets have successfully identified a set of cancer intrinsic factors that could affect the homing and retainment of TILs. We are validating these targets in mouse models and seeking to collaborate with medical sectors to bring our druggable targets to clinic which will hopefully increase efficacy of anti-PD1 treatment greatly.
Competitiondate
202012
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Li, Lin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~